Abstract
Introduction
With a considerable patient population and continued government focus on
lowering national smoking rates, the nicotine dependence market represents a
lucrative opportunity for pharmaceutical companies. With strong uptake since
launch in 2006 of Pfizer' s Chantix (varenicline), the seven major prescription
nicotine dependence market was estimated to total $1.35 billion in 2008.
Key reasons to purchase this research
- Benchmark key late-stage pipeline nicotine dependence projects against
current market leading brands, supported by insight from key opinion leaders.
- Quantify the future market landscape with sales forecasts of marketed,
generics, and key late-stage pipeline drugs to 2018 in the US, 5EU and Japan.
- Understand key events impacting the future nicotine dependence
prescription drug market
Table of Contents
OVERVIEW
- This product contains forecasts for prescribed nicotine dependence
pharmacotherapies across the seven major markets from 2009 to 2018. It has
been designed for delivery in an excel data pack format, but for more detail
about this disease area please see the accompanying Pipeline and Commercial
Insight: Nicotine Dependence word document and PowerPoint executive
presentation (DMHC2482).
- The associated report and PowerPoint presentation can be found under
Latest research in the Knowledge centre, through the search function or by
contacting your sales representative.
- Introduction
- Scope of this research
- Research and analysis highlights
- Key reasons to read this report
- Forecasting Methodology
- The forecasting model:
- General event information:
- Event selection and quantification:
- Event parameters:
| 
